These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27393301)

  • 1. Clinical vertebral fractures following denosumab discontinuation.
    Polyzos SA; Terpos E
    Endocrine; 2016 Oct; 54(1):271-272. PubMed ID: 27393301
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
    Popp AW; Zysset PK; Lippuner K
    Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab: a novel antiresorptive drug for osteoporosis.
    Suresh E; Abrahamsen B
    Cleve Clin J Med; 2015 Feb; 82(2):105-14. PubMed ID: 25897599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.
    De Sousa SMC; Jesudason D
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):250-252. PubMed ID: 30269340
    [No Abstract]   [Full Text] [Related]  

  • 8. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
    Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature.
    Florez H; Ramírez J; Monegal A; Guañabens N; Peris P
    Semin Arthritis Rheum; 2019 Oct; 49(2):197-203. PubMed ID: 30826108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remarkable loss of bone mineral density in 6 months after denosumab discontinuation: a case report.
    Maezumi Y; Kamimura M; Nakamura Y; Takahashi J
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):218-221. PubMed ID: 33087002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-Term Follow-Up of Denosumab Discontinuers with Multiple Vertebral Fractures in the Real-World: A Case Series.
    Tripto-Shkolnik L; Liel Y; Yekutiel N; Goldshtein I
    Horm Metab Res; 2021 Mar; 53(3):185-190. PubMed ID: 33588445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous Vertebral Fractures in Males with Osteoporosis After Denosumab Discontinuation: A Report of Two Cases.
    Anagnostis P; Paschou SA; Gonzalez-Rodriguez E; Potoupnis M; Tsiridis E; Lamy O; Goulis DG
    J Clin Rheumatol; 2021 Dec; 27(8S):S581-S584. PubMed ID: 30614889
    [No Abstract]   [Full Text] [Related]  

  • 14. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
    Lehmann T; Aeberli D
    Osteoporos Int; 2017 Oct; 28(10):3067-3068. PubMed ID: 28589418
    [No Abstract]   [Full Text] [Related]  

  • 15. [Multiple vertebral fractures after denosumab discontinuation].
    Tjelum L; Eiken P
    Ugeskr Laeger; 2018 Nov; 180(45):. PubMed ID: 30404716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warning of an increased risk of vertebral fracture after stopping denosumab.
    Symonds C; Kline G
    CMAJ; 2018 Apr; 190(16):E485-E486. PubMed ID: 29685907
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
    Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
    Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects and management of denosumab discontinuation.
    Chapurlat R
    Joint Bone Spine; 2018 Oct; 85(5):515-517. PubMed ID: 29317292
    [No Abstract]   [Full Text] [Related]  

  • 19. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
    Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
    Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple vertebral fractures following osteoporosis treatment discontinuation: a case-report after long-term Odanacatib.
    Binkley N; Krueger D; de Papp AE
    Osteoporos Int; 2018 Apr; 29(4):999-1002. PubMed ID: 29455249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.